- Home
- KRUS vs ETNB Comparison
KRUS vs ETNB Comparison
Compare KRUS & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRUS
- ETNB
- Stock Information
- Founded
- KRUS 2008
- ETNB 2018
- Country
- KRUS United States
- ETNB United States
- Employees
- KRUS N/A
- ETNB N/A
- Industry
- KRUS Restaurants
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- KRUS Consumer Discretionary
- ETNB Health Care
- Exchange
- KRUS Nasdaq
- ETNB Nasdaq
- Market Cap
- KRUS 990.5M
- ETNB 1.5B
- IPO Year
- KRUS 2019
- ETNB 2019
- Fundamental
- Price
- KRUS $75.49
- ETNB $11.08
- Analyst Decision
- KRUS Buy
- ETNB Strong Buy
- Analyst Count
- KRUS 9
- ETNB 8
- Target Price
- KRUS $94.56
- ETNB $26.43
- AVG Volume (30 Days)
- KRUS 348.9K
- ETNB 1.8M
- Earning Date
- KRUS 07-08-2025
- ETNB 08-04-2025
- Dividend Yield
- KRUS N/A
- ETNB N/A
- EPS Growth
- KRUS N/A
- ETNB N/A
- EPS
- KRUS N/A
- ETNB N/A
- Revenue
- KRUS $269,327,000.00
- ETNB N/A
- Revenue This Year
- KRUS $20.29
- ETNB N/A
- Revenue Next Year
- KRUS $19.75
- ETNB N/A
- P/E Ratio
- KRUS N/A
- ETNB N/A
- Revenue Growth
- KRUS 18.76
- ETNB N/A
- 52 Week Low
- KRUS $40.03
- ETNB $4.16
- 52 Week High
- KRUS $110.66
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- KRUS 42.10
- ETNB 67.40
- Support Level
- KRUS $72.48
- ETNB $9.92
- Resistance Level
- KRUS $93.00
- ETNB $10.34
- Average True Range (ATR)
- KRUS 4.88
- ETNB 0.45
- MACD
- KRUS -1.78
- ETNB 0.05
- Stochastic Oscillator
- KRUS 7.41
- ETNB 98.11
About KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a technology-enabled restaurant concept serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. It offers several dishes, including Dashi Olive Salmon, Tomago, Sweet Shrimp, Tuna, Garlic Tuna Steak, and Salmon, among others.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).